Results 21 to 30 of about 238 (77)
Supplementary Table S6 from Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial
, 2019 Table S6 shows the percentage of MHC class I positive cells in tumor tissue from NIBIT-M4 patients at baseline, at Week 4 and at Week 12.Alessia Covre (6058937), Michele Maio (264944), Carolina Fazio (6058934), Clelia Miracco (329033), Andrea Anichini (2532421), Laetitia Lacroix (14996411), Riccardo Danielli (14994500), James Lowder (5055494), Luca Sigalotti (38328), Monica Valente (15016287), Santa Monterisi (15016293), Mohammad Azab (2936682), Dietmar Rieder (15010043), Zlatko Trajanoski (15774), Amelie Nemc (6506367), Sandra Coral (6058958), Aram Oganesian (2403982), Wolf H. Fridman (15016296), Francesca Finotello (15016284), Florent Petitprez (4729359), Andrea Lazzeri (2295805), Giovanni Amato (15016290), Christoph Bock (9201235), Catherine Sautès-Fridman (15016299), Diana Giannarelli (757148), Ornella Cutaia (6058940), Anna Maria Di Giacomo (13359324) +26 morecore +1 more sourceImmune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study [PDF]
Journal for ImmunoTherapy of Cancer, 2013 Meeting abstracts Ipilimumab (IPI) in combination with fotemustine (FTM) has shown a promising clinical activity in metastatic melanoma (MM) patients (pts) enrolled in the NIBIT-M1 trial (Di Giacomo, et al., Lancet Oncology, 2012).Maccalli, Cristina, Nicolay, Hugues, Capocefalo, Filippo, Fonsatti, Ester, Chiarucci, Carla, Cutaia, Ornella, Giannarelli, Diana, Parmiani, Giorgio, Di Giacomo, Anna, Maio, Michele +9 moreopenaire +1 more sourceSupplementary Table S7 from Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial
, 2019 Table S7 describes the density of different cell type (CD8+ T cell, PD-1+ T cells and CD20+ B cell) in tumor core of samples from NIBIT-M4 patients at baseline, at Week 4 and at Week 12.Alessia Covre (6058937), Michele Maio (264944), Carolina Fazio (6058934), Clelia Miracco (329033), Andrea Anichini (2532421), Laetitia Lacroix (14996411), Riccardo Danielli (14994500), James Lowder (5055494), Luca Sigalotti (38328), Monica Valente (15016287), Santa Monterisi (15016293), Mohammad Azab (2936682), Dietmar Rieder (15010043), Zlatko Trajanoski (15774), Amelie Nemc (6506367), Sandra Coral (6058958), Aram Oganesian (2403982), Wolf H. Fridman (15016296), Francesca Finotello (15016284), Florent Petitprez (4729359), Andrea Lazzeri (2295805), Giovanni Amato (15016290), Christoph Bock (9201235), Catherine Sautès-Fridman (15016299), Diana Giannarelli (757148), Ornella Cutaia (6058940), Anna Maria Di Giacomo (13359324) +26 morecore +1 more sourceSupplementary Fig S2 from Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial
, 2019 Figure shows density of CD20+ cells in the tumor core of NIBIT-M4 patients at different time points during treatment and the correlation between density and patients clinical ...Alessia Covre (6058937), Michele Maio (264944), Carolina Fazio (6058934), Clelia Miracco (329033), Andrea Anichini (2532421), Laetitia Lacroix (14996411), Riccardo Danielli (14994500), James Lowder (5055494), Luca Sigalotti (38328), Monica Valente (15016287), Santa Monterisi (15016293), Mohammad Azab (2936682), Dietmar Rieder (15010043), Zlatko Trajanoski (15774), Amelie Nemc (6506367), Sandra Coral (6058958), Aram Oganesian (2403982), Wolf H. Fridman (15016296), Francesca Finotello (15016284), Florent Petitprez (4729359), Andrea Lazzeri (2295805), Giovanni Amato (15016290), Christoph Bock (9201235), Catherine Sautès-Fridman (15016299), Diana Giannarelli (757148), Ornella Cutaia (6058940), Anna Maria Di Giacomo (13359324) +26 morecore +1 more sourceSupplementary Table S5 from Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial
, 2019 Table S5 lists canonical pathways activated or inhibited in responding vs non-responding NIBIT-M4 patients at baseline, at Week 4 and at W12.Alessia Covre (6058937), Michele Maio (264944), Carolina Fazio (6058934), Clelia Miracco (329033), Andrea Anichini (2532421), Laetitia Lacroix (14996411), Riccardo Danielli (14994500), James Lowder (5055494), Luca Sigalotti (38328), Monica Valente (15016287), Santa Monterisi (15016293), Mohammad Azab (2936682), Dietmar Rieder (15010043), Zlatko Trajanoski (15774), Amelie Nemc (6506367), Sandra Coral (6058958), Aram Oganesian (2403982), Wolf H. Fridman (15016296), Francesca Finotello (15016284), Florent Petitprez (4729359), Andrea Lazzeri (2295805), Giovanni Amato (15016290), Christoph Bock (9201235), Catherine Sautès-Fridman (15016299), Diana Giannarelli (757148), Ornella Cutaia (6058940), Anna Maria Di Giacomo (13359324) +26 morecore +1 more sourceSupplementary Table S1 from Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial
, 2019 Table S1 describes pharmacokinetic parameters (Tmax, time taken to reach peak concentration; Cmax, peak serum concentration; AUC, area under the curve) for decitabine and guadecitabine, by dose of guadecitabine in NIBIT-M4 patients.Alessia Covre (6058937), Michele Maio (264944), Carolina Fazio (6058934), Clelia Miracco (329033), Andrea Anichini (2532421), Laetitia Lacroix (14996411), Riccardo Danielli (14994500), James Lowder (5055494), Luca Sigalotti (38328), Monica Valente (15016287), Santa Monterisi (15016293), Mohammad Azab (2936682), Dietmar Rieder (15010043), Zlatko Trajanoski (15774), Amelie Nemc (6506367), Sandra Coral (6058958), Aram Oganesian (2403982), Wolf H. Fridman (15016296), Francesca Finotello (15016284), Florent Petitprez (4729359), Andrea Lazzeri (2295805), Giovanni Amato (15016290), Christoph Bock (9201235), Catherine Sautès-Fridman (15016299), Diana Giannarelli (757148), Ornella Cutaia (6058940), Anna Maria Di Giacomo (13359324) +26 morecore +1 more sourceEfficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial
, 2020 Background
Brain metastases (BM) represent a high-unmet medical need, in which the therapeutic potential of immune-checkpoint(s) (ICI) is being actively investigated. Temozolomide and fotemustine (FTM) have been the therapeutic mainstay of melanoma (MM) Marchetti, P., Calabrò, L., Guidoboni, M., Gambale, E., Giannarelli, D., Guida, M., Mandala, M., Quaglino, P., Valente, M., Amato, G., Cutaia, O., Di Giacomo, A. M., Sileni, V. C., Danielli, R., Maio, M., Del Vecchio, M., Ferrucci, P. F., Calabrò L, Valente M, Gambale E, Marchetti P, Cutaia O, Mandalà M, Quaglino P, Chiarion-Sileni VC, Maio M, Ferrucci PF, Giannarelli D, Di Giacomo AM, Del Vecchio M, Guida M, Danielli R, Amato G, Guidoboni M, G. Amato, A.M. Di Giacomo, O. Cutaia, M. Guida, M. Valente, L. Calabrò, P.F. Ferrucci, M. Guidoboni, R. Danielli, M. Maio, M. Mandala, P. Marchetti, E. Gambale, M. Del Vecchio, V. Chiarion Sileni, D. Giannarelli, P. Quaglino +50 morecore +1 more sourceSupplementary Table S4 from Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial
, 2019 Table S4 lists canonical pathways that were modulated in tumor samples of NIBIT-M4 patients by treatment, and also describes the number of tumor samples in which the specific pathway was modulated ...Alessia Covre (6058937), Michele Maio (264944), Carolina Fazio (6058934), Clelia Miracco (329033), Andrea Anichini (2532421), Laetitia Lacroix (14996411), Riccardo Danielli (14994500), James Lowder (5055494), Luca Sigalotti (38328), Monica Valente (15016287), Santa Monterisi (15016293), Mohammad Azab (2936682), Dietmar Rieder (15010043), Zlatko Trajanoski (15774), Amelie Nemc (6506367), Sandra Coral (6058958), Aram Oganesian (2403982), Wolf H. Fridman (15016296), Francesca Finotello (15016284), Florent Petitprez (4729359), Andrea Lazzeri (2295805), Giovanni Amato (15016290), Christoph Bock (9201235), Catherine Sautès-Fridman (15016299), Diana Giannarelli (757148), Ornella Cutaia (6058940), Anna Maria Di Giacomo (13359324) +26 morecore +1 more sourceCancer bio-immunotherapy XVI annual NIBIT-(Italian Network for Tumor Biotherapy) meeting, October 11–13 2018, Milan, Italy
Cancer Immunology, Immunotherapy, 2020 Not ...Bellone M, Brevi A, Bruzzì S, Consonni M, De Santis F, Di Lullo G, Majorini MT, PastO' A, Amadori A, Bregni M, Di Nicola M, Calabro' L, Ferrucci PF, Proietti E, Colombo MP, Russo V +15 moreopenaire +4 more sources